Meeting Explores Regulatory Requirements for Parkinson's MCI Michael J. Fox Foundation Conference ...
Similar to Alzheimer's disease, PD dementia begins with subtle deficits in cognition that progress to symptoms recognizable as mild cognitive impairment.
By looking for structural DNA variations in Alzheimer’s families, researchers identified 18 new genes that may play a role in AD pathology.
Eating fewer saturated fats and simple sugars reduces harmful forms of Aβ in the cerebrospinal fluid, scientists report.
In a series of eight reviews, titled "Focus on Neurotechniques," researchers describe how approaches such as optogenetics and stem cells are revolutionizing neuroscience.
The experimental drug NitroMemantine protects synapses from Aβ oligomer toxicity in mice by blocking extrasynaptic NMDA receptors.
An ultra-high-resolution 3D map of the human brain promises to help scientists studying neuroanatomy, neurosurgery, neurodegenerative disease, and more.
Brain imaging distinguishes ALS patients with C9ORF72 expansions from those with other forms of the disease.
Before cognition falters, Alzheimer’s disease wreaks havoc on synapses, the brain’s subcellular communication hubs.
Despite ample evidence implicating Aβ in Alzheimer’s pathology, scientists still struggle to understand how the peptide harms the brain.
Eli Lilly and Company announced yesterday that they have terminated the Phase 2 trial of their BACE inhibitor LY2886721 due to liver abnormalities.
A report on global disease burden found that the number of deaths in China due to Alzheimer’s disease and other dementias doubled between 1990 and 2010.
Researchers have long assumed that people with familial Alzheimer’s disease make too much Aβ42 in the brain, but they lacked proof.
Combination Drug Trials: Time to Open a New Front in AD? Combination Trials: FDA Puts Flesh on Bones of Draft Guidance Combination Trials: Companies Can Play Well in One Sandbox Building a Roadmap for Shared Combination Drug Trials ACT-AD FDA/AD Allies ...
As potential AD drugs continue to post disappointing Phase 2/3 results, many in the field are considering upping the artillery by testing experimental drugs in combination.